AssetMark Inc’s Vir Biotechnology VIR Stock Holding History

AssetMark Inc’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$570	Buy	+51	New	+$510	﹤0.01%	3371

Other funds holding VIR

GSK plc London $497M AUM 35.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Clearstead Advisors Cleveland, Ohio $10.8B AUM 17.88% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Great Lakes Advisors Chicago, Illinois $12.7B AUM 28.72% 1-Year Est. Return

AssetMark Inc's VIR Position: Q3 2026 in Review

AssetMark Inc opened a new position in Vir Biotechnology (VIR) in Q3 2026: 51 shares worth $570. The stake represents ﹤0.01% of the portfolio and ranks #3371 among its holdings.

104 funds tracked by Wall St. Rank hold VIR as of Q3 2026.

AssetMark Inc held 51 shares of Vir Biotechnology worth $570 as of Q3 2026.
Vir Biotechnology was a new AssetMark Inc position in Q3 2026.
Vir Biotechnology made up ﹤0.01% of AssetMark Inc's portfolio in Q3 2026, its #3371 holding.
104 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.